Patients with AAV have been shown to develop elevated LDL-C following diagnosis [24], possibly due to a combination of the treatments they are given and endothelial dysfunction, which has itself been associated with increases in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations in those with kidney impairment [25]. This evidence concerns the gene PCSK9 and endothelial dysfunction.